Entropy Technologies LP Cuts Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Entropy Technologies LP lessened its stake in United Therapeutics Co. (NASDAQ:UTHR) by 43.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,683 shares of the biotechnology company’s stock after selling 1,297 shares during the period. Entropy Technologies LP’s holdings in United Therapeutics were worth $603,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Renaissance Technologies LLC grew its holdings in shares of United Therapeutics by 1.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after acquiring an additional 22,978 shares during the period. LSV Asset Management raised its holdings in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares during the period. Dimensional Fund Advisors LP raised its holdings in United Therapeutics by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after purchasing an additional 22,683 shares during the period. Pacer Advisors Inc. raised its holdings in United Therapeutics by 19.6% in the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after purchasing an additional 92,240 shares during the period. Finally, Swedbank AB bought a new stake in United Therapeutics during the first quarter valued at about $97,316,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on UTHR shares. HC Wainwright raised their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. TD Cowen lifted their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Bank of America dropped their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

Insiders Place Their Bets

In other United Therapeutics news, Director Nilda Mesa sold 224 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $412.28, for a total value of $92,350.72. Following the completion of the sale, the director now directly owns 5,783 shares in the company, valued at $2,384,215.24. This trade represents a 3.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christopher Causey sold 510 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the transaction, the director now directly owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. This represents a 12.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 113,396 shares of company stock worth $42,175,418 over the last 90 days. Company insiders own 11.90% of the company’s stock.

United Therapeutics Stock Down 3.5 %

Shares of NASDAQ:UTHR opened at $386.27 on Friday. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The stock has a market cap of $17.25 billion, a P/E ratio of 16.96, a price-to-earnings-growth ratio of 1.17 and a beta of 0.56. The business’s 50 day moving average is $362.57 and its 200 day moving average is $326.65.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s revenue was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.38 earnings per share. On average, sell-side analysts anticipate that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.